HC Wainwright & Co. Reiterates Buy on Bolt Biotherapeutics, Maintains $7 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $7 price target.